Plasma Surfactant Protein-A Levels In Healthy Subjects And Chronic Obstructive Pulmonary Disease Patients

Area of Science:

• Pulmonary Medicine
• Biomarker Research
• Respiratory Health

Background:

• Chronic Obstructive Pulmonary Disease (COPD) presents a significant global health burden with a lack of effective diagnostic and prognostic biomarkers.
• Systemic Surfactant Protein-A (SP-A) shows potential as it is elevated in smokers and COPD patients.

Purpose of the Study:

• To compare plasma SP-A levels in male and female COPD patients versus healthy individuals.
• To assess the utility of SP-A as a potential biomarker for COPD diagnosis and prognosis.

Main Methods:

• A comparative study involving 84 subjects (30-80 years) divided into four groups.
• COPD diagnosis based on spirometry (post-bronchodilator FEV1/FVC <0.70) and clinical history.
• Plasma SP-A and cotinine levels were measured.

Main Results:

• No significant difference in plasma SP-A levels was observed between COPD patients and controls, or between male and female COPD patients.
• Plasma SP-A levels showed a positive correlation with plasma cotinine levels, indicating a link with tobacco consumption.
• Female COPD patients reported more symptoms and developed the disease at a younger age than male patients, despite similar tobacco exposure.

Conclusions:

• Plasma SP-A levels are not significantly different across the studied groups, suggesting limited value as a standalone COPD biomarker.
• Plasma cotinine levels positively correlate with SP-A, reinforcing the association between SP-A and tobacco use.
• Female patients exhibit earlier onset and potentially more severe symptoms of COPD compared to males with comparable smoking habits.